Your session is about to expire
← Back to Search
68Ga PSMA-11 injection for Prostate Cancer
Study Summary
This trial is testing whether a new kind of PET scan can help doctors better locate prostate cancer lesions.
- Prostate Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this research still enrolling participants?
"Clinicaltrials.gov data indicates that this research project is currently enrolling participants, having been initially posted on 27th January 2020 and most recently updated 21st January 2022."
What is the enrollment capacity for this research trial?
"Affirmative. Clinicaltrials.gov data indicates that this investigation, which was initially displayed on January 27th 2020, is actively looking for participants. A total of 20 people are required to be recruited from a single medical site."
What potential risks can be associated with 68Ga PSMA-11 injection?
"Considering the fact that 68Ga PSMA-11 injection is only at Phase 2 and there is limited data in support of its efficacy, we have assigned it a safety rating of 2."
Share this study with friends
Copy Link
Messenger